CIONIC NEURAL SLEEVE (NS-200)

The Cionic Neural Sleeve NS-200 is a wearable neuromuscular electrical stimulation device consisting of a fabric sleeve with embedded sensors, a battery-powered control unit, and a mobile app. It electrically stimulates leg muscles (shin, calf, quadriceps, hamstrings) to provide ankle and knee movement assistance in adults with foot drop or muscle weakness from upper motor neuron injury, and may also facilitate muscle re-education, prevent disuse atrophy, and provide biofeedback for relaxation and muscle retraining.

The NS-200 uses monophasic hybrid stimulation (not biphasic like the secondary predicate), delivers 100 mA at 500Ω and frequency range of 5–125 Hz, incorporates a 24-channel high-voltage multiplexer to control 8 virtual positive and 15 virtual negative output channels from a single stimulator channel, includes 8 EMG input channels with 2 kHz sampling at 0.0298 μV sensitivity using bipolar detection, and adds new biofeedback modes (Visual Biofeedback Mode and Muscle Activated Stimulation Mode) via software enhancements that leverage existing sEMG functionality without changing hardware.

IEC 60601-1 (general medical device safety), IEC 60601-1-2 (electromagnetic compatibility), IEC 60601-2-10 (muscle and nerve stimulators), IEC 62304 (software lifecycle processes), IEC 62366 (usability), IEC 60601-1-6 (summative usability evaluation), and 21 CFR 898 (electrical safety compliance).

The NS-200 is identical to the primary predicate (NS-100, K221823) in stimulation output modes, channel architecture, battery specifications, and overall intended use for foot drop and muscle weakness. Minor hardware changes (simplified sleeve electronics, enhanced grips, improved Velcro) and the addition of biofeedback software do not alter the fundamental therapeutic mechanism or safety profile. Both devices use the same monophasic hybrid stimulation, equivalent maximum phase charge (40 μC), and pass identical IEC safety standards, demonstrating that the new biofeedback functionality leverages existing sEMG capabilities without introducing new risks or requiring additional clinical evidence.